Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COVETRUS, INC.CVET · Entity 123087 | Director · President and CEO | October 13, 2022 | October 13, 2022 |
| Everyday Health, Inc.EVDY · Entity 180558 | Director · CEO | December 03, 2016 | December 06, 2016 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | June 06, 2019 | June 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COVETRUS, INC.
Report date October 13, 2022 · Filed October 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-13 transaction · row 1
1 source rowRow 1 · 2022-10-13 · Disposition to issuer · Disposed 198,711 · Balance 0 F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-13 · Disposition to issuer · Disposed 351,443 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.
F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.
Everyday Health, Inc.
Report date December 03, 2016 · Filed December 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-12-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2016-12-03 · Other · Disposed 467,077 · Balance 168,172 F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company(the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger"). Row 2 · 2016-12-05 · Other · Acquired 233,331 · Balance 401,503 F2: Acquired pursuant to the exercise of the Performance Warrant, as described below. Row 3 · 2016-12-05 · Disposition to issuer · Disposed 233,331 · Balance 168,172 F3: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding). Row 4 · 2016-12-05 · Disposition to issuer · Disposed 168,172 · Balance 0 F4: Pursuant to the terms of the Reporting Person's employment agreement with the Issuer, the vesting of restricted stock units for an aggregate of 168,172 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.87 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-12-05 · Disposition to issuer · Disposed 30,184 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-12-05 · Disposition to issuer · Disposed 130,090 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.27 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-12-05 · Disposition to issuer · Disposed 133,333 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-12-05 · Disposition to issuer · Disposed 133,333 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.68 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2016-12-05 · Disposition to issuer · Disposed 164,166 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Employee Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $5.00 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-12-05 · Disposition to issuer · Disposed 66,666 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). |
| Call Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2016-12-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2016-12-05 · Other · Disposed 233,331 · Balance 0 F6: Represents a performance warrant (the "Performance Warrant") granted to the Reporting Person and Michael Keriakos, the founders of the Issuer, as reflected in the Performance Warrant Agreement, as amended (the "Performance Warrant Agreement"), by and among the Reporting Person, Mr. Keriakos and certain other stockholders of the Issuer. F7: Pursuant to the Performance Warrant Agreement, and subject to the terms and conditions thereof, beginning on January 1, 2017, the Performance Warrant was to become exercisable, subject to the potential acceleration of exercisability upon the occurrence of a change in control of the Issuer (the "Trigger Date"). Because the Merger constituted a change in control, the Trigger Date occurred on, and the Performance Warrant was exercised effective as of, December 5, 2016. F8: The Performance Warrant was scheduled to expire, if not previously exercised, upon the last day of the year in which the Trigger Date occurred. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a cash tender offer conducted in accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated October 21, 2016, among the Issuer, Ziff Davis, LLC, a Delaware limited liability company(the "Parent"), Project Echo Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and j2 Global, Inc. in exchange for cash consideration of $10.50 per share, without interest and less any applicable tax withholding. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
F2: Acquired pursuant to the exercise of the Performance Warrant, as described below.
F3: Pursuant to the terms of the Merger Agreement, these shares were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).
F4: Pursuant to the terms of the Reporting Person's employment agreement with the Issuer, the vesting of restricted stock units for an aggregate of 168,172 shares was accelerated in connection with the Merger. Pursuant to the terms of the Merger Agreement, these accelerated restricted stock units were cancelled and converted into the right to receive cash consideration of $10.50 per share (without interest and less any applicable tax withholding).
F5: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding).
F6: Represents a performance warrant (the "Performance Warrant") granted to the Reporting Person and Michael Keriakos, the founders of the Issuer, as reflected in the Performance Warrant Agreement, as amended (the "Performance Warrant Agreement"), by and among the Reporting Person, Mr. Keriakos and certain other stockholders of the Issuer.
F7: Pursuant to the Performance Warrant Agreement, and subject to the terms and conditions thereof, beginning on January 1, 2017, the Performance Warrant was to become exercisable, subject to the potential acceleration of exercisability upon the occurrence of a change in control of the Issuer (the "Trigger Date"). Because the Merger constituted a change in control, the Trigger Date occurred on, and the Performance Warrant was exercised effective as of, December 5, 2016.
F8: The Performance Warrant was scheduled to expire, if not previously exercised, upon the last day of the year in which the Trigger Date occurred.
ROCKWELL MEDICAL, INC.
Report date June 06, 2019 · Filed June 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,710 |
Reported balance
After 2019-06-06 transaction · row 1
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 27,710 · Balance 27,710 F1: Restricted stock units vest on June 6, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2029-06-06 | Direct | 22,461 |
Reported balance
After 2019-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-06 · Grant · Acquired 22,461 · Balance 22,461 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on June 6, 2020.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Diplomat Pharmacy, Inc.
Report date February 10, 2020 · Filed February 10, 2020
Section 16 reporting ended · disclosed 2020-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-02-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-10 · Other · Disposed 16,398 · Balance 33,259 F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. Row 2 · 2020-02-10 · Disposition to issuer · Disposed 33,259 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest.
F2: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 3, 2021 16:08 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 89,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-21-000067 · wf-form4_161480570085033.xml · derivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,889 Underlying: Common Stock · 89,889 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Report Person's continuous service as an employee of the Issuer, the RSUs will vest 33% at the one-year anniversary of the grant date, then in equal ratable quarterly increments for the subsequent eight quarters. F2 · derivative.expiration_date: Subject to the Report Person's continuous service as an employee of the Issuer, the RSUs will vest 33% at the one-year anniversary of the grant date, then in equal ratable quarterly increments for the subsequent eight quarters. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $39.13 | $108,707.03 |
DisclosureSEC source: 0001752836-21-000029 · wf-form4_161307750851350.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,360 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F3 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $38.53 - $39.73. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $37.54 | $104,299.45 |
DisclosureSEC source: 0001752836-21-000029 · wf-form4_161307750851350.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,138 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F2 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $37.00 - $37.95. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $37.67 | $104,651.98 |
DisclosureSEC source: 0001752836-21-000024 · wf-form4_161178150888994.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,916 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F3 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $37.23 - $38.25. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $38.29 | $106,362.68 |
DisclosureSEC source: 0001752836-21-000024 · wf-form4_161178150888994.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,694 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F2 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $37.80 - $39.00. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 16:59 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-21-000022 · wf-form4_161161194970830.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,774 Underlying: Common Stock · 21,615 shares Expires 2023-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 16:59 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 6,341 | $39.47 | $250,279.27 |
DisclosureSEC source: 0001752836-21-000022 · wf-form4_161161194970830.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,472 Read SEC document |
| January 21, 2021 Filed Jan 25, 2021 16:59 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-21-000022 · wf-form4_161161194970830.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 16:17 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $29.61 | $82,269.91 |
DisclosureSEC source: 0001752836-20-000210 · wf-form4_160763504256652.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,198 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F4 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $28.99 - $29.97. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 16:17 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $27.99 | $77,765.94 |
DisclosureSEC source: 0001752836-20-000210 · wf-form4_160763504256652.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,976 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F2 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $27.50 - $28.36. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,573 shares acquired under the Covetrus Employee Stock Purchase Plan on November 30, 2020. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,488 | $25.43 | $63,270.09 |
DisclosureSEC source: 0001752836-20-000208 · wf-form4_160581989893034.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,181 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F3 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $25.02 - $25.68. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | SaleCommon Stock | 2,778 | $24.95 | $69,313.60 |
DisclosureSEC source: 0001752836-20-000208 · wf-form4_160581989893034.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,669 F1 · kind: Sale pursuant to 10b5-1 Plan dated August 31, 2020. F2 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $24.56 - $25.56. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000195 · wf-form4_160348358166431.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,389 Underlying: Common Stock · 21,615 shares Expires 2023-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 9,441 | $27.04 | $255,284.64 |
DisclosureSEC source: 0001752836-20-000195 · wf-form4_160348358166431.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,447 Read SEC document |
| October 21, 2020 Filed Oct 23, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000195 · wf-form4_160348358166431.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000183 · wf-form4_159968189787445.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,259 shares Expires 2020-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs vested on the first anniversary of the grant date. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 3,993 | $22.29 | $89,003.97 |
DisclosureSEC source: 0001752836-20-000183 · wf-form4_159968189787445.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,273 Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 9,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000183 · wf-form4_159968189787445.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Aug 13, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000177 · wf-form4_159734917113739.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,004 Underlying: Common Stock · 21,615 shares Expires 2023-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| July 21, 2020 Filed Aug 13, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 6,264 | $21.15 | $132,483.60 |
DisclosureSEC source: 0001752836-20-000177 · wf-form4_159734917113739.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,007 Read SEC document |
| July 21, 2020 Filed Aug 13, 2020 16:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000177 · wf-form4_159734917113739.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000088 · wf-form4_158767233421365.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,619 Underlying: Common Stock · 21,615 shares Expires 2023-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 6,264 | $8.09 | $50,675.76 |
DisclosureSEC source: 0001752836-20-000088 · wf-form4_158767233421365.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,656 Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 16:05 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000088 · wf-form4_158767233421365.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:53 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 6,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000059 · wf-form4_158327241926806.xml · derivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,288 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:53 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 6,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000059 · wf-form4_158327241926806.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:18 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | Disposition to issuerCommon Stock | 33,259 | $4.00 | $133,036.00 |
DisclosureSEC source: 0001104659-20-013516 · a4.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to an Agreement and Plan of Merger, dated December 9, 2019 (the "Merger Agreement"), by and among UnitedHealth Group Incorporated, a Delaware corporation ("Parent"), Purchaser, a Michigan corporation and a wholly owned subsidiary of Parent and Diplomat Pharmacy, Inc., a Michigan corporation (the "Issuer"), each outstanding restricted stock award held by reporting person was disposed of pursuant to the closing on February 10, 2020 of the merger of Purchaser with and into the Issuer. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 16:18 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | OtherCommon Stock | 16,398 | $4.00 | $65,592.00 |
DisclosureSEC source: 0001104659-20-013516 · a4.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · kind: Represents shares tendered to the Denali Merger Sub, Inc. ("Purchaser") in connection with the closing on February 10, 2020 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $4.00 per share in cash, subject to any required withholding of taxes, without interest. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:32 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000016 · wf-form4_157981870624030.xml · derivative · entry 3 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,234 Underlying: Common Stock · 21,615 shares Expires 2023-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:32 UTC | COVETRUS, INC. CVET · Entity 123087 | Tax withholdingCommon Stock | 6,598 | $15.07 | $99,431.86 |
DisclosureSEC source: 0001752836-20-000016 · wf-form4_157981870624030.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,017 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:32 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 21,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-20-000016 · wf-form4_157981870624030.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. Read SEC document |
| October 21, 2019 Filed Oct 23, 2019 17:14 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 345,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-19-000051 · wf-form4_157186522789223.xml · derivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,396 Underlying: Common Stock · 345,849 shares Expires 2023-10-21 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as an employee of the Issuer, the RSUs will vest in equal ratable quarterly increments over the four-year period from October 21, 2019. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 16:57 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | SaleCommon Stock | 859 | $4.84 | $4,157.56 |
DisclosureSEC source: 0001596771-19-000121 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,657 F1 · kind: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F1 · shares: The sales reported in this Form 4 represent shares sold automatically to cover the tax liability incurred incident to the vesting of previously granted restricted stock. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 16:07 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 9,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-19-000043 · wf-form4_156780043282213.xml · derivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,547 Underlying: Common Stock · 9,259 shares Expires 2020-09-04 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Represents shares issuable upon settlement of RSUs granted to the Reporting Person. Each RSU represents a contingent right to receive one share of Issuer's common stock. Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 23:21 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 22,461 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-19-034648 · a4.xml · derivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,461 Underlying: Common Stock · 22,461 shares Expires 2029-06-06 Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 23:21 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 27,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-034648 · a4.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,710 F1 · kind: Restricted stock units vest on June 6, 2020. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:52 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | SaleCommon Stock | 1,274 | $4.85 | $6,184.89 |
DisclosureSEC source: 0001596771-19-000058 · primary_doc.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,516 F2 · kind: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F2 · shares: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F3 · price: The price represents the weighted average price of the multiple transactions reported on this line. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:52 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 33,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-19-000058 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,790 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:07 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantCommon Stock | 6,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005750 · doc4.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 F1 · shares: Represents shares issuable upon settlement of Restricted Stock Units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of Issuer's common stock. Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:40 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 2,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000097 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,531 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's revised non-employee director compensation program, effective October 1, 2018. Read SEC document |
| June 05, 2018 Filed Jun 5, 2018 17:28 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | SaleCommon Stock | 1,679 | $24.27 | $40,743.79 |
DisclosureSEC source: 0001596771-18-000073 · primary_doc.xml · nonDerivative · entry 2 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,256 F2 · kind: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F2 · shares: The sales reported in this Form 4 represent shares sold to cover the tax liability incurred incident to the vesting of previously granted restricted stock. F3 · price: The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $24.21 to $24.46. Upon request by the SEC staff, the Issuer or any securityholder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:28 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 3,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-18-000073 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,935 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 22:10 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 52,501 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001140361-18-014509 · doc1.xml · derivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,501 Underlying: Common Stock · 52,501 shares Expires 2028-03-19 F1 · security: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. F1 · kind: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 17:06 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 4,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-17-000048 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,281 F1 · shares: The shares of restricted stock were granted in connection with the Issuer's non-employee director compensation program. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:18 UTC | Diplomat Pharmacy, Inc. DPLO · Entity 151818 | GrantCommon Stock | 5,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-17-000011 · primary_doc.xml · nonDerivative · entry 1 Wolin Benjamin · CIK 0001492650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,559 F1 · shares: The shares of restricted stock were granted under the Issuer's non-employee director compensation program in connection with Mr. Wolin's appointment as independent Lead Director. The shares vest pro rata annually over two years, with 50% vesting on each of the first and second anniversaries of the grant date. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 17:33 UTC | Everyday Health, Inc. EVDY · Entity 180558 | OtherCall Option (Right to Buy) · Derivative | 233,331 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-153706 · doc4.xml · derivative · entry 11 Wolin Benjamin · CIK 0001492650 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233,331 shares Expires not disclosed F6 · security: Represents a performance warrant (the "Performance Warrant") granted to the Reporting Person and Michael Keriakos, the founders of the Issuer, as reflected in the Performance Warrant Agreement, as amended (the "Performance Warrant Agreement"), by and among the Reporting Person, Mr. Keriakos and certain other stockholders of the Issuer. F7 · derivative.exercise_date: Pursuant to the Performance Warrant Agreement, and subject to the terms and conditions thereof, beginning on January 1, 2017, the Performance Warrant was to become exercisable, subject to the potential acceleration of exercisability upon the occurrence of a change in control of the Issuer (the "Trigger Date"). Because the Merger constituted a change in control, the Trigger Date occurred on, and the Performance Warrant was exercised effective as of, December 5, 2016. F8 · derivative.expiration_date: The Performance Warrant was scheduled to expire, if not previously exercised, upon the last day of the year in which the Trigger Date occurred. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 17:33 UTC | Everyday Health, Inc. EVDY · Entity 180558 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 164,166 | $2.82 Strike: $7.68 | $462,948.12 |
DisclosureSEC source: 0001209191-16-153706 · doc4.xml · derivative · entry 10 Wolin Benjamin · CIK 0001492650 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,166 shares Expires not disclosed F5 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 17:33 UTC | Everyday Health, Inc. EVDY · Entity 180558 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 133,333 | $4.16 Strike: $6.35 | $553,998.62 |
DisclosureSEC source: 0001209191-16-153706 · doc4.xml · derivative · entry 9 Wolin Benjamin · CIK 0001492650 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,333 shares Expires not disclosed F5 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 17:33 UTC | Everyday Health, Inc. EVDY · Entity 180558 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 133,333 | $1.23 Strike: $9.27 | $163,999.59 |
DisclosureSEC source: 0001209191-16-153706 · doc4.xml · derivative · entry 8 Wolin Benjamin · CIK 0001492650 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,333 shares Expires not disclosed F5 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 17:33 UTC | Everyday Health, Inc. EVDY · Entity 180558 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 130,090 | $4.74 Strike: $5.76 | $616,626.60 |
DisclosureSEC source: 0001209191-16-153706 · doc4.xml · derivative · entry 7 Wolin Benjamin · CIK 0001492650 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,090 shares Expires not disclosed F5 · kind: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · price: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, this option was cancelled and converted into the right to receive cash consideration of $10.50 per share subject to such stock option less the exercise price payable per share (without interest and less any applicable tax withholding). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.